¿¬¼ö°­ÁÂ
´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2022-07-16
´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò : 2022-07-16
±³À°ÀÏÀÚ : 2022-07-16
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õ·ë  
±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á½ÉÆ÷Áö¿ò 
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼­¿ïÁöºÎȸ  
´ã´çÀÚ : Á¤ÇýÁ¤ ±³¼ö
¿¬¶ôó : 02-2260-7315  
À̸ÞÀÏ : humeong01@nmc.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ ȸ¿ø ÀÌ¿Ü´Â 50¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:05~14:25 Dupilumab vs JAK Inhibitor for atopic dermatitis  ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:25~14:45 Safer use of JAK inhibitor  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 14:45~15:05 Practical treatment approaches of chronic urticaria in Korea  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
Åä·Ð 07-16 ¶óº¥´õ·ë 15:05~15:15 Q&A  () 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:15~15:35 Treatment of nail dystrophy and ingrowing nail  ¿Àº´È£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:35~15:55 Finasteride vs dutasteride for androgenetic alopecia  ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 15:55~16:15 Supportive and adjunctive treatment for hair loss  ÃÖÀ±Áø(¿¬¼¼º½ºûÇǺΰú) 
Åä·Ð 07-16 ¶óº¥´õ·ë 16:15~16:25 Q&A  () 
È޽Ġ07-16 ¶óº¥´õ·ë 16:25~16:50   () 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 16:50~17:10 Increasing the usefulness of patch test in allergic contact dermatitis  °íÁÖ¿¬(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 17:10~17:30 My experience of hypopigmenting agents including tranexamic acid in clinical practice  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-16 ¶óº¥´õ·ë 17:30~17:50 RF vs HIFU: basic steps for skin rejuvenation  Á¤¿î°æ(À¯¾ØÁ¤ÇǺΰú) 
Åä·Ð 07-16 ¶óº¥´õ·ë 17:50~18:00 Q&A  () 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 8,452 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 8,486 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 8,628 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù) : 2024-05-18

±³À°ÀÏÀÚ : 2024-05-18 ±³À°Àå¼Ò : ¿Â¶óÀÎ (24½Ã°£ VOD ´çÀÏ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 1 , Á¶È¸¼ö : 8,594 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 8,137 , ´ñ±Û¼ö : 0